Pharma

Pharmalot

Pharmalittle: FDA places hold on Novartis trial for gene therapy; FDA floats plan for combating shortages

By Ed Silverman

Biotech

Novartis’ Zolgensma gene therapy study halted by FDA on animal safety concerns

By Adam Feuerstein

Pharmalot

FDA panel recommends removing the Makena drug for preventing premature births

By Ed Silverman

Pharmalot

FDA issues new recommendations to combat drug shortages, but can it really fix the problem?

By Ed Silverman

Pharmalot

Pharmalittle: Rise in drug costs for large employers slows; experimental TB vaccine proves effective

By Ed Silverman

Pharmalot

Will an FDA panel recommend a drug for preventing premature births remain available?

By Ed Silverman

Health

Seniors clamor for high-dose flu shot, but it’s not always easy to find

By Robert Weisman — Boston Globe

Pharmalot

FDA considers a rating system for manufacturing facilities as a way to fight drug shortages

By Ed Silverman

Pharmalot

Pharmalittle: Congress struggles with drug pricing bill; in Utah, pleas on social media for insulin

By Ed Silverman

Pharmalot

Two patient charities settle allegations of helping drug makers pay Medicare kickbacks

By Ed Silverman

Pharmalot

Gilead faces an antitrust complaint in Brazil over hepatitis C pricing

By Ed Silverman

Pharmalot

Up and down the ladder: The latest comings and goings

By Ed Silverman

Pharmalot

Pharmalittle: Democratic drug pricing bill may be unconstitutional; FTC staff OKs Roche deal to buy Spark

By Ed Silverman

Pharmalot

Pharmalittle: States push back on opioid deal; sheriffs acted as front group to decry importation

By Ed Silverman

Pharmalot

After years of battling, Vertex and the U.K. reach a deal for cystic fibrosis medicines

By Ed Silverman

Pharmalot

Despite warnings, many U.K. clinical trial sponsors still fail to report their results

By Ed Silverman

Special Report

The Medicine Hunters, Part II: Toxic weed fuels a cancer-drug gold rush — and a quandary

By Eric Boodman

Pharmalot

A U.K. official says the National Health Service is getting closer to a deal with Vertex

By Ed Silverman

Pharmalot

More new medicines benefited from publicly supported research than you may have thought

By Ed Silverman

Pharmalot

Pharmalittle: Biogen Alzheimer’s drug revival sparks skepticism; docs chide blood-thinner recommendations

By Ed Silverman

Special Report

The Medicine Hunters, Part I: Before signing up for a trial, one patient wants to know if the drug will be affordable

By Eric Boodman

Pharmalot

Biogen’s latest Alzheimer’s drug data may look good, but is it enough for FDA approval?

By Ed Silverman

Pharmalot

Pharmalittle: Biogen resurrects an Alzheimer’s drug; last-minute settlement in a big opioid trial

By Ed Silverman

Pharmalot

Consumers sue Sanofi and other drug makers over Zantac link to a possible carcinogen

By Ed Silverman

Pharmalot

The use of antibiotics in food-producing livestock continues to drop in most of Europe

By Ed Silverman

Pharmalittle: Pelosi claims trade deal shows progress on drug issues; Novartis suffers another trial setback

Giving vouchers to pharma to develop antibiotics could be a costly move

Swiss authorities probe Boehringer Ingelheim and other companies for antitrust practices

Pharmalittle: Pharma keeps slashing jobs in the U.S.; overseas plants have more data integrity violations

Pharmalittle: FDA places hold on Novartis trial for gene therapy; FDA floats plan for combating shortages

Novartis’ Zolgensma gene therapy study halted by FDA on animal safety concerns

FDA panel recommends removing the Makena drug for preventing premature births

FDA issues new recommendations to combat drug shortages, but can it really fix the problem?

Pharmalittle: Rise in drug costs for large employers slows; experimental TB vaccine proves effective

Will an FDA panel recommend a drug for preventing premature births remain available?

Seniors clamor for high-dose flu shot, but it’s not always easy to find

FDA considers a rating system for manufacturing facilities as a way to fight drug shortages

Pharmalittle: Congress struggles with drug pricing bill; in Utah, pleas on social media for insulin

Two patient charities settle allegations of helping drug makers pay Medicare kickbacks

Gilead faces an antitrust complaint in Brazil over hepatitis C pricing

Up and down the ladder: The latest comings and goings

Pharmalittle: Democratic drug pricing bill may be unconstitutional; FTC staff OKs Roche deal to buy Spark

Pharmalittle: States push back on opioid deal; sheriffs acted as front group to decry importation

After years of battling, Vertex and the U.K. reach a deal for cystic fibrosis medicines

Despite warnings, many U.K. clinical trial sponsors still fail to report their results

The Medicine Hunters, Part II: Toxic weed fuels a cancer-drug gold rush — and a quandary

A U.K. official says the National Health Service is getting closer to a deal with Vertex

More new medicines benefited from publicly supported research than you may have thought

Pharmalittle: Biogen Alzheimer’s drug revival sparks skepticism; docs chide blood-thinner recommendations

The Medicine Hunters, Part I: Before signing up for a trial, one patient wants to know if the drug will be affordable

Biogen’s latest Alzheimer’s drug data may look good, but is it enough for FDA approval?

Pharmalittle: Biogen resurrects an Alzheimer’s drug; last-minute settlement in a big opioid trial

Consumers sue Sanofi and other drug makers over Zantac link to a possible carcinogen

The use of antibiotics in food-producing livestock continues to drop in most of Europe